Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Boehringer, Ensemble join forces to discover macrocycle drugs
Pharmaceutical Business Review
Friday, November 2, 2012 - 10:03am
tags:
Boehringer Ingelheim, R&D, contract research, macrocycle drugs, Ensemble Therapeutics
Teva swings to loss on charges but sales growth is strong
Pharma Times, UK
Friday, November 2, 2012 - 9:59am
tags:
Teva Pharmaceuticals, earnings
Valeant Pharma Q3 Profit Declines; Tightens Q4, 2012 EPS Outlook
NASDAQ.com
Friday, November 2, 2012 - 9:57am
tags:
earnings, Valeant Pharmaceuticals
Vertex posts loss as hepatitis drug sales fall
Reuters
Friday, November 2, 2012 - 9:52am
tags:
earnings, Vertex Pharmaceuticals
Why Arena's Launch Will Be Strong, Despite Vivus' Weak Launch
Motley Fool
Thursday, November 1, 2012 - 6:09pm
tags:
Arena Pharmaceuticals, obesity, Vivus, Belviq, Qsymia
Johnson & Johnson Settles 845 Levaquin Lawsuits
Bloomberg
Thursday, November 1, 2012 - 6:07pm
tags:
JNJ, settlements, Levaquin
Endocyte Reports Third Quarter 2012 Financial Results and Business Update
Yahoo
Thursday, November 1, 2012 - 6:07pm
tags:
earnings, Endocyte
Pfizer's Future May Hinge On Tofacitinib FDA Action In November
Seeking Alpha
Thursday, November 1, 2012 - 6:06pm
tags:
FDA, Pfizer, tofacitinib, rheumatoid arthritis
The Gory Details on GlaxoSmithKline's Double Miss
Motley Fool
Thursday, November 1, 2012 - 5:19pm
tags:
GSK, earnings
Pfizer says to make "go or no go" decision by March 2013 on Remoxy
Reuters
Thursday, November 1, 2012 - 12:42pm
tags:
Remoxy, Pfizer
Sanofi draws fire over cost of MS drug Lemtrada
Reuters
Thursday, November 1, 2012 - 11:51am
tags:
MS, multiple sclerosis, Sanofi, Lemtrada
Medivation Prostate Cancer Drug Launches Hot
TheStreet.com
Thursday, November 1, 2012 - 11:50am
tags:
Medivation, prostate cancer, Astellas, Xtandi
Medivir Rises on Plans for Hepatitis C Study: Stockholm Mover
Bloomberg
Thursday, November 1, 2012 - 11:49am
tags:
Medivir, hepatitis C, VX-135, Vertex Pharmaceuticals
The Wild October Ride Of Vivus
Seeking Alpha
Thursday, November 1, 2012 - 11:25am
tags:
Vivus, obesity, Arena Pharmaceuticals
Novartis to Construct $500M Biologics Plant in Singapore
Genetic Engineering News
Thursday, November 1, 2012 - 11:20am
tags:
Novartis, Singapore
Watson CEO Looks Past Actavis Deal to Next Growth Plans
Bloomberg
Thursday, November 1, 2012 - 11:19am
tags:
Watson, Pharma CEOs, Actavis, M&A, generics
Bayer to buy U.S. vitamin maker Schiff for $1.2 bln
Reuters
Thursday, November 1, 2012 - 11:18am
tags:
Bayer, M&A, Schiff, vitamins
GlaxoSmithKline warns on European drug prices
Guardian, UK
Thursday, November 1, 2012 - 11:17am
tags:
Europe, GSK, drug pricing
Isis Means Business With This New Treatment
Wall St. Cheat Sheet
Thursday, November 1, 2012 - 11:16am
tags:
Isis Pharmaceuticals, ISIS-STAT3, chemotherapy, advanced cancer, cancer
Somaxon Pharmaceuticals, Inc.'s CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Thursday, November 1, 2012 - 11:15am
tags:
Somaxon, earnings

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.